Business Context and Reporting Period
Company: Compass Therapeutics, Inc. (CMPX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Compass is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its pipeline targets angiogenesis and the immune system, with lead candidates including tovecimig (DLL4/VEGF-A bispecific), CTX-471 (CD137 agonist), CTX-8371 (PD-1/PD-L1 bispecific), and CTX-10726 (PD-1/VEGF-A bispecific).
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16,633) | $(10,787) |
| Loss Per Share (Basic & Diluted) | $(0.12) | $(0.08) |
| Operating Expenses | $17,966 | $12,770 |
| Research & Development (R&D) | $13,054 | $9,522 |
| General & Administrative (G&A) | $4,912 | $3,248 |
| Other Income (Interest) | $1,333 | $1,983 |
| Cash, Cash Equivalents & Marketable Securities | $112,635 | $106,722 |
| Net Cash Used in Operating Activities | $(13,208) | $(13,888) |
| Accumulated Deficit | $(381,316) | $(326,095) |
Note: Cash, cash equivalents, and marketable securities for Q1 2025 calculated as $41,048 (Cash) + $71,587 (Marketable Securities). Q1 2024 calculated as $23,994 (Cash/Restricted) + $83,239 (Marketable Securities) based on balance sheet and cash flow reconciliation.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by $5.8 million (54%) to $16.6 million, driven primarily by higher operating expenses.
- R&D Expenses: Increased by $3.5 million (37%). The increase was attributed to $2.0 million in additional manufacturing expenses for tovecimig and $1.3 million related to the new program CTX-10726.
- G&A Expenses: Increased by $1.7 million (51%), primarily due to a $1.0 million increase in stock-based compensation and higher bonus expenses.
- Other Income: Decreased by $0.7 million (33%) to $1.3 million, reflecting lower interest income on marketable securities.
- Liquidity: Total cash and marketable securities increased slightly to approximately $113 million, despite operating cash burn, due to net proceeds from the sale of marketable securities ($11.6 million provided by investing activities).
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Clinical Milestones: On April 1, 2025, the company announced that tovecimig met its primary endpoint in a Phase 2/3 study for second-line biliary tract cancer (BTC), achieving a 17.1% overall response rate (ORR) versus 5.3% for paclitaxel alone (p=0.031). Secondary endpoints (PFS, OS) are expected in Q4 2025.
- New Trials: On April 21, 2025, the first patient was dosed in an Investigator Sponsored Trial (IST) for tovecimig in the first-line setting for BTC.
- Capital Runway: Management expects current cash resources ($113 million) to fund operating expenses and capital expenditures into the first quarter of 2027.
- Future Funding: The company anticipates needing substantial additional funding to complete clinical development and potential commercialization. Future financing may involve equity, debt, or strategic collaborations.
Risks and Contingencies
- Tariff Risks: A new risk factor was added regarding potential adverse impacts from U.S. tariff programs announced in early 2025, which could affect global economic conditions and trade.
- Development Uncertainty: As a clinical-stage company, there is no assurance that product candidates will obtain regulatory approval or achieve commercial viability.
- Liquidity Risk: The company has incurred significant losses since inception and has no product revenue. Failure to raise additional capital could force delays or reductions in development programs.
Investor Verification Checklist
- Clinical Data Validation: Verify the statistical significance and clinical relevance of the tovecimig Phase 2/3 primary endpoint results announced in April 2025.
- Cash Burn Rate: Monitor the quarterly cash burn rate against the stated runway into Q1 2027 to assess the timing of potential future capital raises.
- Manufacturing Costs: Review the sustainability of the $2.0 million increase in manufacturing expenses for tovecimig and its impact on future R&D budgets.
- Regulatory Pathway: Confirm the timeline and requirements for the upcoming secondary endpoint readout (PFS/OS) in Q4 2025 and subsequent regulatory filings.
- Stock-Based Compensation: Assess the impact of the $2.5 million quarterly stock-based compensation expense on future dilution and cash flow.